Most GLP-1 Drug Trials Fail to Report What Participants Actually Ate | Research

The takeaway

A scoping review of 129 GLP-1 and tirzepatide clinical trials found that only 28% reported any diet quality or food intake data, despite diet being central to the weight loss these drugs produce.

Only 8% reported diet
Of 129 randomized trials of GLP-1 and tirzepatide medications, only 10 actually reported dietary outcome data — despite diet being central to weight management.

What the researchers found

Of 129 AOM trials, only 36 (28%) collected dietary data, and only 10 (8%) actually reported diet outcomes — revealing a systematic gap in understanding how GLP-1 drugs interact with eating behavior.

Why it matters

GLP-1 drugs are prescribed alongside dietary guidance, yet almost no trials rigorously measure what people eat. Without this data, clinicians cannot distinguish how much weight loss comes from the drug itself versus dietary changes — and cannot optimize nutrition advice for patients on these medications.

How the study worked

Scoping review with systematic literature search in MEDLINE-PubMed through December 2024, screening 129 eligible randomized trials of liraglutide, semaglutide, and tirzepatide.

What this study cannot tell us

As a scoping review, this study maps the landscape of reporting but does not assess the quality of individual trials. The search was limited to MEDLINE-PubMed, potentially missing relevant trials in other databases. The review cannot determine why dietary data is underreported — whether due to study design choices, funding constraints, or publication practices.

How to read the evidence

This is a well-conducted scoping review that systematically identifies a gap in the literature. It does not generate new clinical evidence but provides a strong meta-level critique of existing trial design and reporting.

When this study was published

Published in 2025 with a search through December 2024, capturing the most current trial landscape.

The bigger picture

As GLP-1 drugs become some of the most prescribed medications globally, the lack of dietary data in clinical trials is a significant gap. Understanding how these drugs change eating patterns — food preferences, meal timing, nutrient intake — is essential for preventing nutritional deficiencies, optimizing outcomes, and developing comprehensive obesity care beyond just the injection.

Questions still open

Do GLP-1 drugs change food preferences and nutrient intake in ways that could cause nutritional deficiencies?
Should future GLP-1 trials be required to standardize and report dietary assessments?
How much of the weight loss attributed to GLP-1 drugs is actually driven by concurrent dietary changes versus the drug itself?

Common questions

Do GLP-1 drugs work without dieting?

The drugs reduce appetite and food intake through hormonal mechanisms, so some weight loss occurs regardless of intentional dieting. However, this review reveals that we actually lack good data on what people eat during GLP-1 trials, making it hard to separate drug effects from dietary changes.

Should I track my nutrition while on semaglutide?

Given that clinical trials rarely monitor diet quality, proactive nutrition tracking is a reasonable personal strategy. GLP-1 drugs can significantly reduce food intake, and ensuring adequate protein, vitamins, and minerals is important to prevent deficiencies during rapid weight loss.

Read the original research

Examining the Omission of Dietary Quality Data in Glucagon-Like Peptide 1 Clinical Trials: A Scoping Review.

Advances in nutrition (Bethesda, Md.), 16(10), 100491

View on PubMed ↗Publisher’s paper ↗

Citation

Babazadeh, Demsina; Wyatt, Shawna; Steinberg, Francene M. (2025). Examining the Omission of Dietary Quality Data in Glucagon-Like Peptide 1 Clinical Trials: A Scoping Review.. Advances in nutrition (Bethesda, Md.), 16(10), 100491. https://doi.org/10.1016/j.advnut.2025.100491